Low Dose Aspirin in the Prevention of Preeclampsia in China

Overview

Preeclampsia is one of the three leading causes of maternal morbidity and mortality all over the world. The use of low dose aspirin has been mentioned in several studies with promising results. The investigators decided to evaluate the use of low dose aspirin in Chinese pregnant women, starting between 12+ and 20 weeks of pregnancy, based on clinical characteristics aiming to reduce the incidence of preeclampsia.

Full Title of Study: “Low Dose Aspirin in the Prevention of Preeclampsia in Chinese Pregnant Women.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 19, 2019

Detailed Description

Detailed Description: The investigators will conduct a randomized control trial to estimate the efficacy of low dose aspirin in preventing preeclampsia in Chinese pregnant women who are evaluated with risk factors. The investigators will also obtain biological specimen including maternal blood, cord blood, placenta specimen and etc. for basic science studies. Rationale for Design:There is a lack of evidences or guideline of aspirin using in preventing PE for Chinese women. The investigators will conduct a randomized control trial, which is the 'gold standard' of research design, hoping to answer the question.

Interventions

  • Drug: Aspirin
    • Low dose aspirin(100mg)per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
  • Other: Blank
    • Routine examination during pregnancy.

Arms, Groups and Cohorts

  • Experimental: aspirin
    • Low dose aspirin (100 mg) starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy, taking at night.
  • Other: blank
    • Routine examination during pregnancy.

Clinical Trial Outcome Measures

Primary Measures

  • Prevention of preeclampsia
    • Time Frame: 6 months
    • The number of cases of preeclampsia that appear in both groups before 34 weeks of pregnancy.

Secondary Measures

  • Prevention of preeclampsia at term
    • Time Frame: 6 months
    • The number of cases of preeclampsia that appear in both groups between 37 and 41 weeks of pregnancy.
  • Fetal Growth Restriction
    • Time Frame: 6 months
    • The number of cases of fetal growth restriction, defined as a fetal weight below the 10th percentile and an abnormal umbilical cord doppler that appear in both groups at any given time during pregnancy.
  • Preterm birth
    • Time Frame: 6 months
  • Abruptio placenta
    • Time Frame: 6 months
    • The number of cases of abruptio placenta that appear in both groups at any given time during pregnancy.
  • Maternal hemorrhage and neonatal intracranial hemorrhage
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

1. Gestational age between 12+ and 20 weeks of pregnancy 2. High risk of preeclampsia, based in clinical risk factors as: 2.1 if they have one or more of the following risk factors: Preeclampsia in a previous pregnancy ,Diabetes Mellitus(Type 1 or 2),Chronic Hypertension . 2.2 if they have two or more of the following risk factors: Pre-pregnancy Body Mass Index ≥28kg/m2, Elderly pregnancy(age ≥35 years), Mother or sisters with preeclampsia in a previous pregnancy, Primiparity or Famliy history (Mother or sister that developed preeclampsia in a previous pregnancy). 3. Signed informed consent. Exclusion Criteria:

1. Allergy to aspirin 2. Asthma 3. Peptic ulcers 4. Severe heart, liver, renal disease who can not burden the experiment 5. Rheumatic immune disease 6. Mental disease 7. Alcohol and drug abuse 8. Being in another drug experiment within 3 months 9. Difficult to follow-up

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking University First Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Li Lin, PhD – Peking University First Hospital
  • Overall Official(s)
    • Huixia Yang, PhD, Study Chair, Peking University First Hospital

References

Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88. No abstract available.

LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Dec 2;161(11):819-26. doi: 10.7326/M14-1884.

WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. Geneva: World Health Organization; 2011. Available from http://www.ncbi.nlm.nih.gov/books/NBK140561/

Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014 May 20;160(10):695-703. doi: 10.7326/M13-2844.

Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004659. doi: 10.1002/14651858.CD004659.pub2.

Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S; Guideline Development Group. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. 2010 Aug 25;341:c2207. doi: 10.1136/bmj.c2207. No abstract available.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.